MED Community Fair Values
Create NarrativeSee what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Medifast, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$10.96 |
| 52週高値 | US$15.46 |
| 52週安値 | US$9.22 |
| ベータ | 0.67 |
| 1ヶ月の変化 | -9.42% |
| 3ヶ月変化 | 7.45% |
| 1年変化 | -25.14% |
| 3年間の変化 | -88.25% |
| 5年間の変化 | -96.13% |
| IPOからの変化 | 99.27% |
最新ニュース
ナラティブの更新 • Jun 25
MED: Leadership Transition And Higher Future P/E Will Support Upside Potential
Analysts have modestly adjusted their price target on Medifast, reflecting updated assumptions for discount rate, revenue trends, profit margins, and a higher future P/E multiple. These factors together temper near-term earnings expectations while slightly lifting the valuation framework in dollar terms.ナラティブの更新 • Jun 06
MED: Leadership Transition And Margin Outlook Will Shape Balanced Future Profile
Analysts have modestly adjusted their price target on Medifast, reflecting updated views on the discount rate, expected profit margins near 8.1%, and an anticipated P/E around 9.7x, which together suggest a slightly different risk and valuation profile for the stock. What's in the News The board has appointed Nicholas Johnson as Chief Executive Officer, effective June 1, 2026.ナラティブの更新 • May 19
MED: Insurance Reimbursement And Metabolic Health Science Will Support Balanced Outlook
Analysts have reduced their Medifast price targets to reflect updated assumptions that now indicate a slower revenue decline, improved profit margins, and a lower forward P/E. Taken together, these factors reset estimated fair value closer to $12.Recent updates
ナラティブの更新 • Jun 25
MED: Leadership Transition And Higher Future P/E Will Support Upside Potential
Analysts have modestly adjusted their price target on Medifast, reflecting updated assumptions for discount rate, revenue trends, profit margins, and a higher future P/E multiple. These factors together temper near-term earnings expectations while slightly lifting the valuation framework in dollar terms.ナラティブの更新 • Jun 06
MED: Leadership Transition And Margin Outlook Will Shape Balanced Future Profile
Analysts have modestly adjusted their price target on Medifast, reflecting updated views on the discount rate, expected profit margins near 8.1%, and an anticipated P/E around 9.7x, which together suggest a slightly different risk and valuation profile for the stock. What's in the News The board has appointed Nicholas Johnson as Chief Executive Officer, effective June 1, 2026.ナラティブの更新 • May 19
MED: Insurance Reimbursement And Metabolic Health Science Will Support Balanced Outlook
Analysts have reduced their Medifast price targets to reflect updated assumptions that now indicate a slower revenue decline, improved profit margins, and a lower forward P/E. Taken together, these factors reset estimated fair value closer to $12.Seeking Alpha • May 12
Medifast: Worth Putting On A Watchlist
Summary Medifast has continued to report concerning financials. A shrinking coach network lowers revenues, and costs remain too high. A turnaround can't be written off quite yet. MED's coach productivity has improved clearly, and a shift to a metabolic health focus from weight loss could work out. Negative enterprise value clearly implies upside potential; I estimate 47% upside to $18.5 if MED's earnings stabilize over the mid-term. Such upside is speculative, though. Read the full article on Seeking Alphaナラティブの更新 • May 03
MED: Insurance Reimbursement And Metabolic Health Data Will Support Balanced Long-Term Outlook
Analysts have modestly adjusted their price target on Medifast, reflecting small tweaks to assumptions around the discount rate, profit margin, and future P/E, while maintaining a fair value of $12.00. These changes together point to a slightly refined view of the company’s risk and earnings outlook.ナラティブの更新 • Apr 18
MED: Metabolic Health Initiatives And Insurance Access Will Support Balanced Long-Term Outlook
Analyst price targets for Medifast have been reset, with updated assumptions pointing to a fair value of $12.00 per share. This is now based on a slightly higher discount rate, a similar revenue outlook, a higher profit margin and a lower forward P/E, which analysts cite as the main drivers of the change.ナラティブの更新 • Apr 04
MED: Future Leadership And Metabolic Health Expansion Will Support Long-Term Upside
Analysts have marginally adjusted their price target on Medifast, reflecting slightly higher assumed profit margins and a modestly higher discount rate while keeping fair value at $12. They are framing this as a fine tuning of expectations rather than a major shift in outlook.ナラティブの更新 • Mar 20
MED: Future Leadership Shift Will Seek To Unlock Metabolic Health Opportunity
Analysts have slightly revised their price target on Medifast, with the updated fair value holding at $12.00 as small adjustments to the discount rate and future P/E assumptions refine the underlying model rather than indicate a major change in outlook. What's in the News OPTAVIA’s comprehensive metabolic health system is now eligible for reimbursement on select insurance plans via HSA and FSA funds, which can allow some clients to use pre tax dollars toward program costs (Product related announcement).ナラティブの更新 • Mar 05
MED: Future Leadership Shift Will Align With New Metabolic Health System
Analysts have modestly reduced their price target on Medifast, citing a slightly lower discount rate, a small improvement in projected profit margin, and a shift to a lower future P/E assumption. Together, these factors point to a more cautious valuation framework in dollar terms.ナラティブの更新 • Feb 19
MED: Future Leadership Shift Will Present Long Term Opportunity
Analysts have trimmed their price target for Medifast from $15 to $12, citing updated assumptions that point to softer revenue growth, lower profit margins, and a higher future P/E multiple. What's in the News Medifast issued earnings guidance for the first quarter of 2026, projecting revenue between US$65,000,000 and US$80,000,000 and a loss per share in a range of US$0.15 to US$0.70 (company guidance).分析記事 • Jul 03
Benign Growth For Medifast, Inc. (NYSE:MED) Underpins Its Share Price
With a price-to-sales (or "P/S") ratio of 0.3x Medifast, Inc. ( NYSE:MED ) may be sending bullish signals at the...分析記事 • May 01
Medifast, Inc. (NYSE:MED) Just Reported, And Analysts Assigned A US$15.00 Price Target
It's been a good week for Medifast, Inc. ( NYSE:MED ) shareholders, because the company has just released its latest...Seeking Alpha • Jan 20
Medifast: Strong Balance Sheet, But I Lack Conviction In The Turnaround
Summary Medifast enjoyed record profits immediately after the pandemic. The emergence of GLP-1 medications has driven revenue, income, and the number of active Optavia coaches down. Management has laid out a strategy for Medifast to acquire customers who are taking GLP-1s, starting with a collaboration with LifeMD. With a strong balance sheet, but without enough conviction of the success of their strategy, I rate Medifast a Hold. Read the full article on Seeking Alpha分析記事 • Jan 09
An Intrinsic Calculation For Medifast, Inc. (NYSE:MED) Suggests It's 41% Undervalued
Key Insights Medifast's estimated fair value is US$26.41 based on 2 Stage Free Cash Flow to Equity Medifast's US$15.64...分析記事 • Dec 11
Medifast, Inc.'s (NYSE:MED) Business And Shares Still Trailing The Industry
You may think that with a price-to-sales (or "P/S") ratio of 0.3x Medifast, Inc. ( NYSE:MED ) is a stock worth checking...
新しいナラティブ • Nov 10
GLP-1 Medication Surge And Stalling Coach Productivity Threaten Revenue Decline
The adoption of weight loss medications impacts Medifast's business model, threatening future revenue and customer acquisition.Seeking Alpha • Nov 06
Medifast: Earnings Surprise, New AI Technologies, And Extremely Undervalued
Summary Medifast reported better-than-expected quarterly EPS and is investing in new marketing strategies, AI technologies, and supply chain optimization to drive future growth. Despite a decline in the number of coaches and productivity, MED trades close to its book value and continues to generate free cash flow. The company's stock repurchase plan and significant cash reserves indicate confidence in future growth, with a potential valuation target of $78 per share. Risks include declining coach numbers, competition from GLP-1 medications, and short-selling pressures, but MED's current valuation appears undervalued. Read the full article on Seeking AlphaSeeking Alpha • Sep 03
Medifast: Reorganization, GLP-1 Medication, And FCF Imply Undervaluation
Summary Medifast's collaboration with LifeMD and acquisition of LifeMD shares are expected to boost business growth and free cash flow. The company's holistic approach combining weight loss formulas, coaches, and GLP-1 medication is a significant competitive advantage. Recent investments in marketing and supply chain optimization initiatives, including the Maryland Distribution Center closure, are likely to enhance FCF margins. Despite recent lower-than-expected EPS, MED's long-term financial growth and undervaluation suggest strong future stock price potential. Read the full article on Seeking AlphaSeeking Alpha • Aug 27
Medifast Business Continues To Shrink, Stock Still Risky
Summary Medifast's stock has plummeted, with dividends still suspended and earnings and revenue are in rapid decline. Despite a strong balance sheet, Medifast faces increased competition and market volatility, leading to a shrinking business. Revenue and earnings are expected to continue declining, making the stock less attractive with higher P/E ratios. Medifast's cash generation has diminished, and the company is focusing on growth rather than dividends, making it a risky investment. Read the full article on Seeking AlphaSeeking Alpha • Jun 26
Medifast: GLP-1 Fears Are Overblown, But Proof Points For Turnaround Are Still Missing
Summary Medifast is a leader in dietary weight management that fell off a cliff since 2022 due to inflationary pressures, the re-opening of restaurants, and the rise of GLP-1 drugs. The company's turnaround plan aims to combine OPTAVIA offerings with direct access to GLP-1 medication through a partnership with LifeMD. At about $20 per share, Medifast may be in deep value territory, but strong negative momentum and the lack of turnaround proof points make it a HOLD at this time. Investors who seek long exposure with an increased margin of safety could consider selling $12.50 MED puts, noting that the company holds over $14 of net cash per share. Read the full article on Seeking AlphaSeeking Alpha • May 24
Medifast: Significant Undervaluation Even As Struggles Persist
Summary Medifast's financial performance is deteriorating rapidly due to the emergence of drug-weight loss competitors. The company reported a significant decline in revenue and earnings in Q1 2023. Medifast is laying off employees and may need to further reduce its workforce to match the revenue drop. My valuation analysis suggests that the stock is significantly undervalued, but I consider this fair given all the challenges. Read the full article on Seeking Alpha分析記事 • May 24
At US$22.76, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?
Medifast, Inc. ( NYSE:MED ), might not be a large cap stock, but it received a lot of attention from a substantial...分析記事 • May 24
Lacklustre Performance Is Driving Medifast, Inc.'s (NYSE:MED) 32% Price Drop
To the annoyance of some shareholders, Medifast, Inc. ( NYSE:MED ) shares are down a considerable 32% in the last...分析記事 • May 06
Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings
Medifast, Inc.'s ( NYSE:MED ) earnings announcement last week didn't impress shareholders. While the headline numbers...分析記事 • May 01
The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...Seeking Alpha • Mar 20
Medifast: Cheap Valuation, Uncertain Future
Summary Medifast has had a successful past with continuous growth and strong financial metrics in the health and wellness industry. However, the dynamic nature of the industry raises concerns about the company's future, particularly when considering the recent rise of GLP-1 medications. Investors should consider the implications of industry changes before making a decision on Medifast as an investment. Read the full article on Seeking AlphaSeeking Alpha • Mar 07
Medifast Is Getting Attractive
Summary Medifast is experiencing a decline in stock price despite a strong business and consistent cash flow. The company's focus on health and wellness, along with its strategic alliance with LifeMD, positions it for significant upside. Medifast's Optavia solution offers a comprehensive approach to weight loss and has a large addressable market. Shares are a buy with price target of $60. Read the full article on Seeking Alpha株主還元
| MED | US Personal Products | US 市場 | |
|---|---|---|---|
| 7D | 2.4% | 5.2% | 1.6% |
| 1Y | -25.1% | -16.1% | 18.6% |
業界別リターン: MED過去 1 年間で-16.1 % の収益を上げたUS Personal Products業界を下回りました。
リターン対市場: MEDは、過去 1 年間で18.6 % のリターンを上げたUS市場を下回りました。
価格変動
| MED volatility | |
|---|---|
| MED Average Weekly Movement | 7.9% |
| Personal Products Industry Average Movement | 8.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: MED 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: MEDの 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1980 | 380 | Nicholas Johnson | medifastinc.com |
メディファスト社は、その子会社を通じて、米国で習慣に基づく、コーチの指導による減量のためのライフスタイル・ソリューションを提供する健康・ウェルネス企業として運営されている。同社は、バー、シリアル、スナックストロー、ホットチョコレート、ハーティチョイス、オートミール、パンケーキ、プリン、ソフトサーブ、シェイク、スムージー、ソフトベイク、スープ、アミノ酸ブレンド、ホエイプロテイン、ホット飲料、ブラウニー、ミニミールからなる減量、体重管理、健康生活製品を、エッセンシャルフューリングス、オプタビア・アセンド、オプタビア・アクティブのカテゴリーで提供しており、マルチビタミン、ミネラル、オメガ3脂肪酸サプリメントを含む毎日の栄養パックも提供している。また、強力で的を絞った脂肪燃焼を活性化することで、体の代謝を的を絞ってリセットする「ライフスタイルプラン」、すべての食品群を食べ続けたい、または健康的な体重を達成するための柔軟な食事プランを希望する顧客向けに設計された「オプティマルウェイト4＆2＆1プラン」「オプティマルウェイト4＆2アクティブプラン」、顧客の長期的な体重管理をサポートする個別化アプローチ「オプタビア最適化プラン」、顧客が減量に集中できるようにするGLP-1薬の栄養補助食品「オプタビアGLP-1栄養サポートプラン」も提供している。さらに、同社は代謝シンクロナイゼーションを提供している。代謝シンクロナイゼーションは、体内の代謝をリセットすることで、代謝機能障害を回復させる科学である。同社は、eコマース・プラットフォーム上で実行されるPOS取引を通じて製品を販売している。同社は健康とウェルネスの消費者にサービスを提供している。以前はHealthrite, Inc.として知られていたが、2001年5月にMedifast, Inc.に社名変更した。メディファスト社は1980年に法人化され、メリーランド州ボルチモアに本社を置いている。
Medifast, Inc. 基礎のまとめ
| MED 基礎統計学 | |
|---|---|
| 時価総額 | US$112.37m |
| 収益（TTM） | -US$20.02m |
| 売上高(TTM) | US$346.10m |
0.3x
P/Sレシオ-5.6x
PER（株価収益率MED は割高か？
公正価値と評価分析を参照収益と収入
| MED 損益計算書（TTM） | |
|---|---|
| 収益 | US$346.10m |
| 売上原価 | US$103.41m |
| 売上総利益 | US$242.70m |
| その他の費用 | US$262.72m |
| 収益 | -US$20.02m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -1.95 |
| グロス・マージン | 70.12% |
| 純利益率 | -5.79% |
| 有利子負債／自己資本比率 | 0% |
MED の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/06 19:49 |
| 終値 | 2026/07/02 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Medifast, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8
| アナリスト | 機関 |
|---|---|
| John San Marco | Brean Capital Historical (Janney Montgomery) |
| Kara Anderson | B. Riley Securities, Inc. |
| Scott Van Winkle | Canaccord Genuity |